Comparative Analysis And Development Forecast Of Domestic And Global Monoclonal Antibody Drug Industry

The production technology of monoclonal antibody drugs is one of the fastest growing of the modern pharmaceutical technologies, and one of the most widely used clinical application of biological technologies. Monoclonal antibody drugs originated hybridoma technology birth in1975which allows mass production of high-affinity murine monoclonal antibodies. Monoclonal antibodies specifically recognize targets of capacities, which have a good homogeneity and specificity. Monoclonal antibodies have been widely applied in experimental study and diagnosis of diseases nowadays. The treatment effect is greatly strengthened for the humanized monoclonal antibody development, and the clinical application of monoclonal antibody drugs get more attention which has become an ideal drug. Monoclonal antibody drugs currently used to treat cancer, autoimmune diseases and infectious diseases, especially with an excellent effect on cancer.This paper stated development process of domestic and abroad, current research, R&D progress and market analysis of monoclonal antibody drugs. In order to provide comprehensive theoretical basis for research and development biopharmaceutical companies and scientists by Contrastive analyzed and development forecast of monoclonal antibody drugs. The current development of monoclonal antibody drugs industry in China has just entered the initial stage, although the policy support was significantly increased and the market average annual compound growth rate increased year by year, there is a big gap compared with the United States and the European Union. This subject stated the domestic monoclonal antibody drug development technical barriers,development opportunities, development situation and prospects of the research promote domestic monoclonal antibody drugs to flourish. Monoclonal antibody drugs play an important role in the pharmaceutical biotechnology in recent years. Monoclonal antibody drugs’global sale is$300million in1997and reached$66.3billion in2012, which get an average annual compound growth rate of over30%. Global sales of drugs of the top ten in five are monoclonal antibody drugs. Monoclonal anibody drugs become the fastest growing and most profitable in the pharmaceutical industry. With genomics and proteomics depth research, more and more development-related human disease targets are identified, antibody drugs development will have a broader space for innovation and design improvement, and will be a breakthrough product for resolved human health problems.